ea0056p299 | Cardiovascular Endocrinology and Lipid Metabolism | ECE2018
Garcia Carmen Hernandez
, Perdigones Cristina Maria Diaz
, Fuentes Miguel Damas
, Martinez Clara Estaun
, Ramos Andrea Sanchez
, Ramos Ana Molina
, Madueno Francisco Tinahones
Introduction and objectives: The treatment with monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) is a new group of drugs that allows us to reach the therapeutic targets of low density cholesterol (LDL-c) in patients intolerant to statins or those who despite treatment with maximum doses of them do not obtain a proper lipid control.Material and methods: We performed a descriptive observational study. We include all ...